Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium

Objectives: Describe the demographic variables, types of liver tumor, surgeries performed and survival children diagnosed with liver tumor undergoing surgical treatment.Method: A retrospective analysis was performed in patients with pediatric liver tumors undergoing surgical treatment, from January 2010 to December 2015 at the "General Oncology Hospital. Solon Espinoza Ayala”. Results: Data from our study reported a diagnosis of hepatoblastoma in 51.85% of all pediatric liver tumors; 50% are routine controls without evidence of disease, 14.28% have been completed clinical treatment, 21.42% died from a second primary diagnosis with metastasis, and another 14.28% (only surgery) who were not followed up because they were transfers from another health system; with respect to global survival it was 64%. The ages ranged from 0 to 15 years old with an average of 5.5. Conclusion: It is very important a timely detection and adequate treatment by a specialized center and trained professionals, liver surgery is a very important chapter for the treatment of liver tumors. The surgical approach with tumor-free resection along with multidisciplinary treatment is the goal for healing.

Download Full-text

Outcomes of Central Hepatectomy for Pediatric Liver Tumors

Journal of Surgical Research ◽

10.1016/j.jss.2021.06.077 ◽

2021 ◽

Vol 268 ◽

pp. 570-575

Author(s):

Stephanie Y Chen ◽

Abigail K Zamora ◽

Danny Lascano ◽

Shengmei Zhou ◽

Eugene S Kim ◽

...

Keyword(s):

Liver Tumors ◽

Pediatric Liver ◽

Pediatric Liver Tumors ◽

Central Hepatectomy

Download Full-text

Gene expression profiling in hepatoblastoma cases of the Japanese Study Group for Pediatric Liver Tumors-2 (JPLT-2) trial

10.31487/j.ejmc.2018.01.003 ◽

2019 ◽

Author(s):

Eiso Hiyama

Keyword(s):

Gene Expression ◽

Gene Expression Profiling ◽

Expression Profiling ◽

Liver Tumors ◽

Study Group ◽

Japanese Study ◽

Pediatric Liver ◽

Pediatric Liver Tumors

Download Full-text

Percutaneous liquid ablation agent for tumor treatment and drug delivery

Science Translational Medicine ◽

10.1126/scitranslmed.abe3889 ◽

2021 ◽

Vol 13 (580) ◽

pp. eabe3889

Author(s):

Hassan Albadawi ◽

Zefu Zhang ◽

Izzet Altun ◽

Jingjie Hu ◽

Leila Jamal ◽

...

Keyword(s):

Liver Transplantation ◽

Ionic Liquid ◽

Liver Tumor ◽

Thermal Ablation ◽

Liver Tumors ◽

Low Cost ◽

Drug Distribution ◽

Tumor Model ◽

Ablation Zone ◽

Synergistic Cytotoxicity

Percutaneous locoregional therapies (LRTs), such as thermal ablation, are performed to limit the progression of hepatocellular carcinoma (HCC) and offer a bridge for patients waiting for liver transplantation. However, physiological challenges related to tumor location, size, and existence of multiple lesions as well as safety concerns related to potential thermal injury to adjacent tissues may preclude the use of thermal ablation or lead to its failure. Here, we showed a successful injection of an ionic liquid into tissue under image guidance, ablation of tumors in response to the injected ionic liquid, and persistence (28 days) of coinjected chemotherapy with the ionic liquid in the ablation zone. In a rat HCC model, the rabbit VX2 liver tumor model, and 12 human resected tumors, injection of the ionic liquid led to consistent tumor ablation. Combining the ionic liquid with the chemotherapy agent, doxorubicin, resulted in synergistic cytotoxicity when tested with cultured HCC cells and uniform drug distribution throughout the ablation zone when percutaneously injected into liver tumors in the rabbit liver tumor model. Because this ionic liquid preparation is simple to use, is efficacious, and has a low cost, we propose that this new LRT may bridge more patients to liver transplantation.

Download Full-text

Pathology of Pediatric Liver Tumors

Pediatric Liver Tumors - Pediatric Oncology ◽

10.1007/978-3-642-14504-9_9 ◽

2010 ◽

pp. 83-112 ◽

Cited By ~ 8

Author(s):

Arthur Zimmermann ◽

Dolores Lopez-Terrada

Keyword(s):

Liver Tumors ◽

Pediatric Liver ◽

Pediatric Liver Tumors

Download Full-text

Liver Transplantation for Pediatric Liver Cancer

Cancers ◽

10.3390/cancers12030720 ◽

2020 ◽

Vol 12 (3) ◽

pp. 720 ◽

Cited By ~ 3

Author(s):

Rakesh Sindhi ◽

Vinayak Rohan ◽

Andrew Bukowinski ◽

Sameh Tadros ◽

Jean de Ville de Goyet ◽

...

Keyword(s):

Liver Transplantation ◽

Liver Cancer ◽

Liver Tumors ◽

Current Knowledge ◽

Tumor Staging ◽

Steady Increase ◽

Malignant Rhabdoid Tumor ◽

Diagnostic Uncertainty ◽

Pediatric Liver ◽

Improvement In Survival

Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series.

Download Full-text

Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol

Journal of Clinical Oncology ◽

10.1200/jco.19.01067 ◽

2020 ◽

Vol 38 (22) ◽

pp. 2488-2498 ◽

Cited By ~ 1

Author(s):

Eiso Hiyama ◽

Tomoro Hishiki ◽

Kenichiro Watanabe ◽

Kohmei Ida ◽

Yuka Ueda ◽

...

Keyword(s):

Late Effects ◽

Low Dose ◽

Liver Tumors ◽

Survival Rates ◽

Late Complications ◽

Malignant Neoplasms ◽

Study Group ◽

Hematopoietic Stem ◽

Japanese Study ◽

Pediatric Liver

PURPOSE We report here the outcomes and late effects of the Japanese Study Group for Pediatric Liver Tumors (JPLT)-2 protocol, on the basis of cisplatin-tetrahydropyranyl-adriamycin (CITA) with risk stratification according to the pretreatment extent of disease (PRETEXT) classification for hepatoblastoma (HB). PATIENTS AND METHODS From 1999 to 2012, 361 patients with untreated HB were enrolled. PRETEXT I/II patients were treated with up-front resection, followed by low-dose CITA (stratum 1) or received low-dose CITA, followed by surgery and postoperative chemotherapy (stratum 2). In the remaining patients, after 2 cycles of CITA, responders received the CITA regimen before resection (stratum 3), and nonresponders were switched to ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC; stratum 4). Intensified chemotherapeutic regimens with autologous hematopoietic stem-cell transplantation (SCT) after resection were an optional treatment for patients with refractory/metastatic disease. RESULTS The 5-year event-free and overall survival rates of HB patients were 74.2% and 89.9%, respectively, for stratum 1, 84.8% and 90.8%%, respectively, for stratum 2, 71.6% and 85.9%%, respectively, for stratum 3, and 59.1% and 67.3%%, respectively, for stratum 4. The outcomes for CITA responders were significantly better than those for nonresponders, whose outcomes remained poor despite salvage therapy with a second-line ITEC regimen or SCT. The late effects, ototoxicity, cardiotoxicity, and delayed growth, occurred in 61, 18, and 47 patients, respectively. Thirteen secondary malignant neoplasms (SMNs), including 10 leukemia, occurred, correlating with higher exposure to pirarubicin and younger age at diagnosis. CONCLUSION The JPLT-2 protocol achieved up-front resectability in PRETEXT I/II patients with no annotation factors, and satisfactory survival in patients who were CITA responders in the remaining patients. However, outcomes for CITA nonresponders were unsatisfactory, despite therapy intensification with ITEC regimens and SCT. JPLT-2 had a relatively low incidence of cardiotoxicity but high rates of SMNs.

Download Full-text

132Liver transplantation for pediatric liver tumors

Liver Transplantation ◽

10.1016/s1527-6465(05)80160-1 ◽

2000 ◽

Vol 6 (3) ◽

pp. C33-C33

Author(s):

J BUELL ◽

A YOSHIDA ◽

S LIMSCIMCHREM ◽

S KELLEY ◽

P BOONE ◽

...

Keyword(s):

Liver Tumors ◽

Pediatric Liver ◽

Pediatric Liver Tumors

Download Full-text

Identification of new liver tumor biomarkers using proteomics.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e21091 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e21091-e21091

Author(s):

Peter J. Maimonis ◽

Yoh Zen ◽

David J. Britton ◽

Andrew Brand ◽

Malcolm Ward ◽

...

Keyword(s):

Liver Tumor ◽

Liver Tumors ◽

Early Stage ◽

Normal Liver ◽

Liver Parenchyma ◽

Tissue Type ◽

P Value ◽

Tumor Biomarkers ◽

Formalin Fixed Paraffin Embedded ◽

New Biomarkers

e21091 Background: It is crucial to identify new biomarkers that help diagnose cancers at an early stage and contribute to the development of new anti-cancer drugs. Here, we identify new liver tumor biomarkers using proteomics. Methods: We evaluated 9 types of liver tissue from 55 patients: normal liver parenchyma (n=7), hepatocellular carcinoma (HCC) (n=7), normal bile duct (n=6), peripheral cholangiocarcinoma (CC) (n=7), hilar CC (n=7), CC associated with primary sclerosing cholangitis (PSC) (n=7), metastatic colorectal cancer (n=7), and mixed HCC/CC after trans-arterial chemoembolization (n=7; areas of HCC and areas of CC separately examined). Protein extracted from microdissected, formalin-fixed paraffin-embedded tissue (0.15 mm3 in total) was reduced, alkylated and digested with trypsin in a stacking gel. Peptides were analyzed using nano-liquid chromatography-Mass spectrometry. The raw data were searched using Mascot. Normalized spectral counts for each protein among each tissue type were compared. For each comparison, an unrelated t-test was computed to obtain the p value. q values (adjusted p values) were computed using a direct False Discovery Rate approach (q < 0.05 considered statistically significant). Results: The mean number of proteins identified per sample was 762 +/- 119 S.D, resulting in a total of 2643 proteins identified. Numbers of proteins with significantly different expression levels among different tissue types are shown below. Some of these proteins are being reported here for the first time in the context of liver carcinogenesis. Conclusions: This study revealed proteins that are significantly over/underexpressed in particular types of liver tumors. Clinically useful new biomarkers may be present among these proteins and are now undergoing validation using immunohistochemisty. [Table: see text]

Download Full-text